{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,7,8]],"date-time":"2026-07-08T02:10:36Z","timestamp":1783476636923,"version":"3.55.0"},"reference-count":33,"publisher":"Oxford University Press (OUP)","issue":"12","license":[{"start":{"date-parts":[[2022,1,12]],"date-time":"2022-01-12T00:00:00Z","timestamp":1641945600000},"content-version":"vor","delay-in-days":0,"URL":"https:\/\/academic.oup.com\/journals\/pages\/open_access\/funder_policies\/chorus\/standard_publication_model"}],"funder":[{"DOI":"10.13039\/501100002347","name":"BMBF","doi-asserted-by":"publisher","award":["01KG1104"],"award-info":[{"award-number":["01KG1104"]}],"id":[{"id":"10.13039\/501100002347","id-type":"DOI","asserted-by":"publisher"}]}],"content-domain":{"domain":[],"crossmark-restriction":false},"short-container-title":[],"published-print":{"date-parts":[[2022,11,23]]},"abstract":"<jats:title>ABSTRACT<\/jats:title>\n               <jats:sec>\n                  <jats:title>Background<\/jats:title>\n                  <jats:p>Angiotensin-converting enzyme inhibitors (ACEis) have evolved as a first-line therapy for delaying end-stage renal failure (ESRF) in Alport syndrome (AS). The present study tested the hypothesis of a superior nephroprotective potential of an early ACEi intervention, examining a cohort with the COL4A5 missense variant p.(Gly624Asp).<\/jats:p>\n               <\/jats:sec>\n               <jats:sec>\n                  <jats:title>Methods<\/jats:title>\n                  <jats:p>In this observational cohort study (NCT02378805), 114 individuals with the identical gene variant were explored for age at ESRF and life expectancy in correlation with treatment as endpoints.<\/jats:p>\n               <\/jats:sec>\n               <jats:sec>\n                  <jats:title>Results<\/jats:title>\n                  <jats:p>All 13 untreated hemizygous patients developed ESRF (mean age 48.9 \u00b1 13.7 years), as did 3 very late treated hemizygotes (51.7 \u00b1 4.2 years), with a mean life expectancy of 59.2 \u00b1 9.6 years. All 28 earlier-treated [estimated glomerular filtration rate (eGFR) \u226560\u00a0mL\/min\/1.73 m2] hemizygous patients were still alive and still had not reached ESRF. Therapy minimized the annual loss of their GFR, similar to the annual loss in healthy individuals. Of 65 heterozygotes, 4 untreated individuals developed ESRF at an age of 53.3 \u00b1 20.7 years. None of the treated heterozygous females developed ESRF.<\/jats:p>\n               <\/jats:sec>\n               <jats:sec>\n                  <jats:title>Conclusions<\/jats:title>\n                  <jats:p>For the first time, this study shows that in AS, early therapy in individuals with missense variants might have the potential to delay renal failure for their lifetime and thus to improve life expectancy and quality of life without the need for renal replacement therapy. Some treated patients have reached their retirement age with still-functioning kidneys, whereas their untreated relatives have reached ESRF at the same or a younger age. Thus, in children with glomerular haematuria, early testing for Alport-related gene variants could lead to timely nephroprotective intervention.<\/jats:p>\n               <\/jats:sec>","DOI":"10.1093\/ndt\/gfac006","type":"journal-article","created":{"date-parts":[[2022,1,10]],"date-time":"2022-01-10T12:09:21Z","timestamp":1641816561000},"page":"2496-2504","source":"Crossref","is-referenced-by-count":33,"title":["Lifelong effect of therapy in young patients with the <i>COL4A5<\/i> Alport missense variant p.(Gly624Asp): a prospective cohort study"],"prefix":"10.1093","volume":"37","author":[{"given":"Jan","family":"Boeckhaus","sequence":"first","affiliation":[{"name":"Clinic for Nephrology and Rheumatology, University Medical Center G\u00f6ttingen , G\u00f6ttingen, Germany"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-7917-7129","authenticated-orcid":false,"given":"Julia","family":"Hoefele","sequence":"additional","affiliation":[{"name":"Institute of Human Genetics, School of Medicine, Klinikum rechts der Isar, Technical University of Munich , Munich, Germany"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-7503-5801","authenticated-orcid":false,"given":"Korbinian M","family":"Riedhammer","sequence":"additional","affiliation":[{"name":"Institute of Human Genetics, School of Medicine, Klinikum rechts der Isar, Technical University of Munich , Munich, Germany"},{"name":"Department of Nephrology, School of Medicine, Klinikum rechts der Isar, Technical University of Munich , Munich, Germany"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Mato","family":"Nagel","sequence":"additional","affiliation":[{"name":"Center for Nephrology and Metabolic Medicine , Weisswasser, Germany"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Bodo B","family":"Beck","sequence":"additional","affiliation":[{"name":"Institute of Human Genetics, Center for Molecular Medicine Cologne, and Center for Rare and Hereditary Kidney Disease, Faculty of Medicine and University Hospital Cologne, University of Cologne, Cologne, Germany"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Mira","family":"Choi","sequence":"additional","affiliation":[{"name":"Department of Nephrology and Medical Intensive Care, Charit\u00e9\u2013Universit\u00e4tsmedizin Berlin , Berlin, Germany"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Maik","family":"Gollasch","sequence":"additional","affiliation":[{"name":"Department of Internal and Geriatric Medicine, University Medicine Greifswald, Greifswald, Germany"},{"name":"Experimental and Clinical Research Center, Charit\u00e9 University Medicine Berlin , Berlin, Germany"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Carsten","family":"Bergmann","sequence":"additional","affiliation":[{"name":"Department of Medicine, Nephrology, University Hospital Freiburg , Germany"},{"name":"Medizinische Genetik Mainz, Limbach Genetics , Mainz, Germany"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Joseph E","family":"Sonntag","sequence":"additional","affiliation":[{"name":"Clinic for Nephrology and Rheumatology, University Medical Center G\u00f6ttingen , G\u00f6ttingen, Germany"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Victoria","family":"Troesch","sequence":"additional","affiliation":[{"name":"Clinic for Nephrology and Rheumatology, University Medical Center G\u00f6ttingen , G\u00f6ttingen, Germany"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Johanna","family":"Stock","sequence":"additional","affiliation":[{"name":"Clinic for Nephrology and Rheumatology, University Medical Center G\u00f6ttingen , G\u00f6ttingen, Germany"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-8390-8852","authenticated-orcid":false,"given":"Oliver","family":"Gross","sequence":"additional","affiliation":[{"name":"Clinic for Nephrology and Rheumatology, University Medical Center G\u00f6ttingen , G\u00f6ttingen, Germany"}],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"286","published-online":{"date-parts":[[2022,1,12]]},"reference":[{"key":"2022112304493762100_bib1","doi-asserted-by":"crossref","first-page":"1888","DOI":"10.1016\/S0140-6736(17)30788-2","article-title":"Global kidney health 2017 and beyond: a roadmap for closing gaps in care, research, and policy","volume":"390","author":"Levin","year":"2017","journal-title":"Lancet"},{"key":"2022112304493762100_bib2","doi-asserted-by":"crossref","first-page":"856","DOI":"10.1016\/S0140-6736(18)33000-9","article-title":"Glomerular podocytes in kidney health and disease","volume":"393","author":"Assady","year":"2019","journal-title":"Lancet"},{"key":"2022112304493762100_bib3","doi-asserted-by":"crossref","first-page":"142","DOI":"10.1056\/NEJMoa1806891","article-title":"Diagnostic utility of exome sequencing for kidney disease","volume":"380","author":"Groopman","year":"2019","journal-title":"N Engl J Med"},{"key":"2022112304493762100_bib4","doi-asserted-by":"crossref","first-page":"1269","DOI":"10.1038\/ejhg.2014.254","article-title":"Clinical utility ene card for: Alport syndrome\u2014update 2014","volume":"23","author":"Hertz","year":"2015","journal-title":"Eur J Hum Genet"},{"key":"2022112304493762100_bib5","doi-asserted-by":"crossref","first-page":"2543","DOI":"10.1056\/NEJMra022296","article-title":"Alport's syndrome, Goodpasture's syndrome, and type IV collagen","volume":"348","author":"Hudson","year":"2003","journal-title":"N Engl J Med"},{"key":"2022112304493762100_bib6","doi-asserted-by":"crossref","first-page":"170","DOI":"10.1038\/nrneph.2012.259","article-title":"Alport syndrome\u2014insights from basic and clinical research","volume":"9","author":"Kruegel","year":"2013","journal-title":"Nat Rev Nephrol"},{"key":"2022112304493762100_bib7","doi-asserted-by":"crossref","first-page":"1045","DOI":"10.1016\/j.kint.2017.12.018","article-title":"Alport syndrome: a unified classification of genetic disorders of collagen IV \u03b1345: a position paper of the Alport Syndrome Classification Working Group","volume":"93","author":"Kashtan","year":"2018","journal-title":"Kidney Int"},{"key":"2022112304493762100_bib8","doi-asserted-by":"crossref","first-page":"494","DOI":"10.1038\/ki.2011.407","article-title":"Early angiotensin-converting enzyme inhibition in Alport syndrome delays renal failure and improves life expectancy","volume":"81","author":"Gross","year":"2012","journal-title":"Kidney Int"},{"key":"2022112304493762100_bib9","doi-asserted-by":"crossref","first-page":"560","DOI":"10.1053\/j.ajkd.2021.02.326","article-title":"Clinical and genetic features of autosomal dominant Alport syndrome: a cohort study","volume":"78","author":"Furlano","year":"2021","journal-title":"Am J Kidney Dis"},{"key":"2022112304493762100_bib10","doi-asserted-by":"crossref","first-page":"438","DOI":"10.1046\/j.1523-1755.2003.00779.x","article-title":"Preemptive ramipril therapy delays renal failure and reduces renal fibrosis in COL4A3-knockout mice with Alport syndrome","volume":"63","author":"Gross","year":"2003","journal-title":"Kidney Int"},{"key":"2022112304493762100_bib11","doi-asserted-by":"crossref","first-page":"615","DOI":"10.1038\/sj.ki.5002115","article-title":"Choosing a mouse model to study the molecular pathobiology of Alport glomerulonephritis","volume":"71","author":"Cosgrove","year":"2007","journal-title":"Kidney Int"},{"key":"2022112304493762100_bib12","doi-asserted-by":"crossref","first-page":"250","DOI":"10.1016\/j.matbio.2018.04.008","article-title":"Alport syndrome and Pierson syndrome: diseases of the glomerular basement membrane","volume":"71\u201372","author":"Funk","year":"2018","journal-title":"Matrix Biol"},{"key":"2022112304493762100_bib13","doi-asserted-by":"crossref","first-page":"1275","DOI":"10.1016\/j.kint.2019.12.015","article-title":"A multicenter, randomized, placebo-controlled, double-blind phase 3 trial with open-arm comparison indicates safety and efficacy of nephroprotective therapy with ramipril in children with Alport's syndrome","volume":"97","author":"Gross","year":"2020","journal-title":"Kidney Int"},{"key":"2022112304493762100_bib14","doi-asserted-by":"crossref","first-page":"1605","DOI":"10.1016\/j.kint.2020.06.038","article-title":"Genotype\u2013phenotype correlations influence the response to angiotensin-targeting drugs in Japanese patients with male X-linked Alport syndrome","volume":"98","author":"Yamamura","year":"2020","journal-title":"Kidney Int"},{"key":"2022112304493762100_bib15","doi-asserted-by":"crossref","first-page":"e0161802","DOI":"10.1371\/journal.pone.0161802","article-title":"X-linked and autosomal recessive Alport syndrome: pathogenic variant features and further genotype-phenotype correlations","volume":"11","author":"Savige","year":"2016","journal-title":"PLoS One"},{"key":"2022112304493762100_bib16","first-page":"207","article-title":"X-linked, COL4A5 hypomorphic Alport mutations such as G624D and P628L may only exhibit thin basement membrane nephropathy with microhematuria and late onset kidney failure","volume":"17","author":"Pierides","year":"2013","journal-title":"Hippokratia"},{"key":"2022112304493762100_bib17","doi-asserted-by":"crossref","first-page":"485","DOI":"10.3389\/fped.2019.00485","article-title":"The hypomorphic variant p.(Gly624Asp) in COL4A5 as a possible cause for an unexpected severe phenotype in a family with X-linked Alport syndrome","volume":"7","author":"Macheroux","year":"2019","journal-title":"Front Pediatr"},{"key":"2022112304493762100_bib18","doi-asserted-by":"crossref","first-page":"1451","DOI":"10.1016\/j.kint.2020.10.040","article-title":"Mild X-linked Alport syndrome due to the COL4A5 G624D variant originating in the Middle Ages is predominant in Central\/East Europe and causes kidney failure in midlife","volume":"99","author":"\u017burowska","year":"2021","journal-title":"Kidney Int"},{"key":"2022112304493762100_bib19","doi-asserted-by":"crossref","first-page":"205","DOI":"10.1016\/j.phrs.2016.03.017","article-title":"RAAS inhibition and the course of Alport syndrome","volume":"107","author":"Savva","year":"2016","journal-title":"Pharmacol Res"},{"key":"2022112304493762100_bib20","doi-asserted-by":"crossref","first-page":"711","DOI":"10.1007\/s00467-020-04819-6","article-title":"Clinical practice recommendations for the diagnosis and management of Alport syndrome in children, adolescents, and young adults-an update for 2020","volume":"36","author":"Kashtan","year":"2021","journal-title":"Pediatr Nephrol"},{"key":"2022112304493762100_bib21","doi-asserted-by":"crossref","first-page":"272","DOI":"10.1053\/j.ajkd.2020.03.026","article-title":"Alport syndrome: achieving early diagnosis and treatment","volume":"77","author":"Kashtan","year":"2021","journal-title":"Am J Kidney Dis"},{"key":"2022112304493762100_bib22","doi-asserted-by":"crossref","first-page":"629","DOI":"10.1681\/ASN.2008030287","article-title":"New equations to estimate GFR in children with CKD","volume":"20","author":"Schwartz","year":"2009","journal-title":"J Am Soc Nephrol"},{"key":"2022112304493762100_bib23","doi-asserted-by":"crossref","first-page":"1844","DOI":"10.1016\/S0140-6736(14)60659-0","article-title":"Rare inherited kidney diseases: challenges, opportunities, and perspectives","volume":"383","author":"Devuyst","year":"2014","journal-title":"Lancet"},{"key":"2022112304493762100_bib24","doi-asserted-by":"crossref","first-page":"649","DOI":"10.1681\/ASN.V114649","article-title":"X-linked Alport syndrome: natural history in 195 families and genotype- phenotype correlations in males","volume":"11","author":"Jais","year":"2000","journal-title":"J Am Soc Nephrol"},{"key":"2022112304493762100_bib25","doi-asserted-by":"crossref","first-page":"2603","DOI":"10.1097\/01.ASN.0000090034.71205.74","article-title":"X-linked Alport syndrome: natural history and genotype\u2013phenotype correlations in girls and women belonging to 195 families: a \u201cEuropean Community Alport Syndrome Concerted Action\u201d study","volume":"14","author":"Jais","year":"2003","journal-title":"J Am Soc Nephrol"},{"key":"2022112304493762100_bib26","doi-asserted-by":"crossref","first-page":"131","DOI":"10.1007\/s00467-016-3452-z","article-title":"Prospective study on the potential of RAAS blockade to halt renal disease in Alport syndrome patients with heterozygous mutations","volume":"32","author":"Stock","year":"2017","journal-title":"Pediatr Nephrol"},{"key":"2022112304493762100_bib27","doi-asserted-by":"crossref","first-page":"1639","DOI":"10.1056\/NEJMoa0902066","article-title":"Strict blood-pressure control and progression of renal failure in children","volume":"361","author":"W\u00fchl","year":"2009","journal-title":"N Engl J Med"},{"key":"2022112304493762100_bib28","doi-asserted-by":"crossref","first-page":"2225","DOI":"10.1681\/ASN.2018010036","article-title":"Early proteinuria lowering by angiotensin-converting enzyme inhibition predicts renal survival in children with CKD","volume":"29","author":"van den Belt","year":"2018","journal-title":"J Am Soc Nephrol"},{"key":"2022112304493762100_bib29","doi-asserted-by":"crossref","first-page":"143","DOI":"10.1111\/cge.13861","article-title":"Precise variant interpretation, phenotype ascertainment, and genotype-phenotype correlation of children in the EARLY PRO-TECT Alport trial","volume":"99","author":"Boeckhaus","year":"2021","journal-title":"Clin Genet"},{"key":"2022112304493762100_bib30","doi-asserted-by":"crossref","first-page":"1400","DOI":"10.1016\/j.kint.2020.07.011","article-title":"Angiotensin-converting enzyme inhibitors in patients with Alport syndrome: can all patients benefit?","volume":"98","author":"Rheault","year":"2020","journal-title":"Kidney Int"},{"key":"2022112304493762100_bib31","doi-asserted-by":"crossref","first-page":"1602","DOI":"10.1681\/ASN.2020020151","article-title":"GFR in healthy aging: an individual participant data meta-analysis of iohexol clearance in European population-based cohorts","volume":"31","author":"Eriksen","year":"2020","journal-title":"J Am Soc Nephrol"},{"key":"2022112304493762100_bib32","doi-asserted-by":"crossref","first-page":"1272","DOI":"10.1093\/ndt\/gfz131","article-title":"New therapeutic options for Alport syndrome","volume":"34","author":"Torra","year":"2019","journal-title":"Nephrol Dial Transplant"},{"key":"2022112304493762100_bib33","doi-asserted-by":"crossref","first-page":"2371","DOI":"10.1056\/NEJMe1904740","article-title":"Clinical credence\u2014SGLT2 inhibitors, diabetes, and chronic kidney disease","volume":"380","author":"Ingelfinger","year":"2019","journal-title":"N Engl J Med"}],"container-title":["Nephrology Dialysis Transplantation"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/academic.oup.com\/ndt\/advance-article-pdf\/doi\/10.1093\/ndt\/gfac006\/43288774\/gfac006.pdf","content-type":"application\/pdf","content-version":"am","intended-application":"syndication"},{"URL":"https:\/\/academic.oup.com\/ndt\/article-pdf\/37\/12\/2496\/47203036\/gfac006.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"syndication"},{"URL":"https:\/\/academic.oup.com\/ndt\/article-pdf\/37\/12\/2496\/47203036\/gfac006.pdf","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2022,11,23]],"date-time":"2022-11-23T04:50:18Z","timestamp":1669179018000},"score":1,"resource":{"primary":{"URL":"https:\/\/academic.oup.com\/ndt\/article\/37\/12\/2496\/6505139"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2022,1,12]]},"references-count":33,"journal-issue":{"issue":"12","published-online":{"date-parts":[[2022,1,12]]},"published-print":{"date-parts":[[2022,11,23]]}},"URL":"https:\/\/doi.org\/10.1093\/ndt\/gfac006","relation":{},"ISSN":["0931-0509","1460-2385"],"issn-type":[{"value":"0931-0509","type":"print"},{"value":"1460-2385","type":"electronic"}],"subject":[],"published-other":{"date-parts":[[2022,12]]},"published":{"date-parts":[[2022,1,12]]}}}